Diagnosis of ovarian carcinoma
    3.
    发明公开
    Diagnosis of ovarian carcinoma 有权
    诊断von Ovarialkarzinom

    公开(公告)号:EP2913673A1

    公开(公告)日:2015-09-02

    申请号:EP14179937.9

    申请日:2002-08-29

    Abstract: Provided are methods of screening for the presence of ovarian carcinoma in a subject. The methods involved contacting a blood, serum, or plasma sample from the subject with an antibody specific for the polypeptide of SEQ ID NO:11. This allows determination of the presence in the biological sample of a molecule that naturally occurs in soluble form, and has an antigenic determinant that is reactive with the antibody. This, in turn, allows detection of the presence of a malignant condition in the subject. The antibody may be a monoclonal antibody, such as a murine monoclonal antibody. Detection of the binding of the antibody to the antigenic determinant may be effected via spectrophotometric detection of a product of an enzyme reaction, for example via enzyme linked immunosorbent assay (ELISA). The subject may have an early stage of ovarian cancer.

    Abstract translation: 提供筛选受试者卵巢癌存在的方法。 所述方法包括使来自受试者的血液,血清或血浆样品与对SEQ ID NO:11的多肽具有特异性的抗体接触。 这允许确定天然以可溶形式发生的分子的生物样品中的存在,并且具有与抗体反应的抗原决定簇。 这反过来又允许检测受试者中是否存在恶性病症。 抗体可以是单克隆抗体,例如鼠单克隆抗体。 抗体与抗原决定簇的结合的检测可以通过酶反应的产物的分光光度法检测,例如通过酶联免疫吸附测定(ELISA)进行。 受试者可能有卵巢癌的早期阶段。

    METHODS AND COMPOSITIONS FOR DIAGNOSING CARCINOMAS
    4.
    发明公开
    METHODS AND COMPOSITIONS FOR DIAGNOSING CARCINOMAS 有权
    方法和组合物用于癌症诊断

    公开(公告)号:EP1169645A2

    公开(公告)日:2002-01-09

    申请号:EP00908795.8

    申请日:2000-02-25

    CPC classification number: C07K16/3069 G01N33/57449 G01N33/57488

    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.

    METHODS AND COMPOSITIONS FOR DIAGNOSING CARCINOMAS
    7.
    发明授权
    METHODS AND COMPOSITIONS FOR DIAGNOSING CARCINOMAS 有权
    方法和组合物用于癌症诊断

    公开(公告)号:EP1169645B1

    公开(公告)日:2006-05-31

    申请号:EP00908795.8

    申请日:2000-02-25

    CPC classification number: C07K16/3069 G01N33/57449 G01N33/57488

    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.

Patent Agency Ranking